FORM PTO-1449

U.S. Department of Commerce Patent & Trademark Office

DEC 0 7 2001

INFORMATION DISCLOSURE STATEMENT

(Use several sheets in Trademark)

Attorney Docket No. 1830/50325

Serial No. 09/933,717

Applicant: Masahiro IMOTO, et al.

Filing Date August 22, 2001

Group

			U.S	. PATE	NT DOCUMENTS					
Examiner Initial		Document Number	Date		Name	Class	Sub- Class		ing I	ate riate)
	AA									
			FOREI	GN PA	TENT DOCUMENTS				·	
Examiner		Document					Sub-		NSLAT	•
Initial	AB	Number	Date		Name	Class	Class	Yes		No
		ER DOCUMENTS (Including A	uthor	, Title, Date, Pe	ertinent Pa	lanes.	etc.)		
H.C.	AC	P. De SARNO, "	Modulation o	of Acet	cylcholine Release	by Nicotini	.c			
1	AD	LEVIN, et al. function in an			choline involvement nacology, 1998	in cogniti	.ve	V		
	AE	, ·	Receptors: I	essons	sity of Neuronal N from Behavior and 1995		ns for	0		
AF SALOMAN, et al. "Nicotine Inhibits Peptide" Biochemistry, 1996					ts Amyloid Formati	ion by the E	3-	J.		
AG KIHARA, et al. "Nicotinic Receptor Stimulation Protects Neurons Against B-Amyloid Toxicity" American Neurological Association, 1997							٢			
AH SANDBORN, et al. "Transdermal Nicotine for Mildly to Modera Active Ulerative Colitis" American College of Physicians, 2							-	مش		
	AI		with Aging		Muscarinic Subtype ementia" Journal of			/		
	AJ	NEWHOUSE, et a pilot study" P			cotine in Alzheime 1988	er's disease	e: a			
·	AK .	GALZI, et al. and Regulation			e Receptors: Molecu ogy, 1995	ılar Organiz	ation	<u> </u>		
	AL	Acetylcholine	Receptors ar	re Pote	Responses of Neuron entiated by a Novel Molecular Pharmacol	l Class of	.c /			
	AM				s in neuronal nicot ications, 1998	inic acetyl	cholin	e /		
	AN	BARRANTES, "Mo Receptor" The Future Trends,	Nicotinic Ad	nology cetylch	of the Nicotinic Anoline Receptor: Co	Acetylcholin urrent Views	ne s and _			
H.C.	AO	LENA, et al. " Physiology, 19		nicotin	nic receptors, huma	an pathologi	es" J.	V		
EXAMINE	R		Hony for	٤	DATE CONSIDERED	3/30/	103			
EXAMINER:					t citation is in confor ered. Include copy of					

FORM PTO-1449

U.S. Department of Commerce Patent & Trademark Office

Attorney Docket No. 1830/50325

Serial No. 09/933,717

Applicant: Masahiro IMOTO, et al.

INFORMATION DISCLOSURE STATEMENT (Use several sheets in necessary)

Filing Date August 22, 2001 Group

			U.S	. PATE	NT DOCUMENTS							
Examiner Initial		Document Number	Date		Name	Class	Sub- Class	Filin (if appr	g Date			
	AP						1	(III Spp.	<u> </u>			
	.		FOREI	GN PAT	ENT DOCUMENTS	· · · · · · · · · · · · · · · · · · ·		· · · · · · · · · · · · · · · · · · ·				
Examiner		Document					Sub-	TRANSLATION				
Initial	,	Number	Date		Name	Class	Class	Yes	No.			
	AQ]					
	OTHE	R DOCUMENTS (1	Including A	uthor,	Title, Date,	Pertinent P	ages,	etc.)	1			
H.L.	AR	TACHIBANA, et al. "Xenon Contrast CT-CBF Scanning of the Brain Differentiates Normal Age-Related Changes for Multi-Infarct Dementia and Senile Dementia of Alzheimer Type" Journal of Gerontology, 1984										
	AS				em Involvement i harmacology, 199		s and					
	AT	MAELICKE, et a dementia" Else			o drug therapy i 1996 €	n Alzheimer':	s	1				
	AU	•			inic Acetylcholi nal of Medicinal	•		0				
	AV	SHACKA, et al. Medicinal Chem			pheral Anatomy o 96 🌶	f Nicotinic	Sites"	,				
	AW		stration of		ing and memory i cotinic receptor							
	AX	Nicotinic Acet	ylcholine Re	eceptor	cterization of t Ligand GTS-21 I and Behavior, 1	n Vitro and						
	AY		In Vitro Ch	naracte	icotinic Agonist rization" Journa 996 °		ology					
	AZ		In Vitro Ch	naracte	icotinic Agonist rization" Journa 996 •		ology					
	ва		ylcholine	Recept	of Subtype-Selor Agonist as							
	вв	Receptor Chann	el by the Ni	itromet	e Neuronal Nicot hylene Heterocyc rimental Therape	le Imidaclop:	rid"					
H.L.	вс	with the Nicot	inic Acetylo	choline	dacloprid Metabo Receptor of Mou try and Physiolo	se Brain in 1		on C				
EXAMINE	ER	Afri.	ng shi		DATE CONSIDERE	D 3/30	/-3					
EXAMINER:	Ini cit	tial if citation con ation_if_not in conf	/ nsidered, whethe formance and not	er or not t conside	citation is in confered. Include copy of	ormance with MPE f this form with	P 609; Di	raw line t mmunicatio	hrough			

Attorney Docket No. 1830/50325

Serial No. 09/933,717

Applicant: Masahiro IMOTO, et al.

Filing Date August 22, 2001

Group

Initial	Document Number		Date	Name	Class	Sub- Class	Filing Date (if appropriate			
	BD							•		
			FOREI	GN PATENT DOCUMENTS						
Examiner Initial	Document Number		Date	Name	Class	Sub- Class	TRANSLATION Yes No			
	BE									
	OTHE	ER DOCUMENTS (Including A	author, Title, Date, Pe	ertinent Pa	ages,	etc.)			
Hill	BF	differential s	ubtype selec	nanges in nicotinoid inse ctivity for mammalian nic British Journal of Pharma	cotinic					
	BG	COSFORD, et al. "(S)-(-)-5-Ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine Maleate 9SIB-1508Y): A Novel Anti-Parkinsonian Agent with Selectivity for Neuronal Nicotinic Acetylcholine Receptors" J. Med. Chem., 1996								
	ВН	DECKER, et al. "ABT-089 [2-Methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine dihydrochloride]: II. A Novel Cholinergic Channel Modulator with Effects on Cognitive Performance in Rats and Monkeys" Journal of Pharmacology and Experimental Therapeutics, 1997 4								
	BI SULLIVAN, et al. "ABT-089 [2-Methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine]: ① A Potent and Selective Cholinergic Channel Modulator with Neuroprotective Properties" Journal of Pharmacology and Experimental Therapeutics, 1997									
	вЈ	(ABT 418): A A	nxiolytic Ad	chyl-5-(1-Methyl-2-Pyrrol ctivities: I. <i>In <u>Vitro C</u></i> nd Experimental Therapeut	aracterizat	ion"				
l hi.	вк	BK DECKER, et al. ""(S)-3-Methyl-5-(1-Methyl-2-Pyrrolidinyl) Isoxazole (ABT 418): A Novel Cholinergic Ligand with Cognition-Enhancing and Anxiolytic Activities: (II) In Vivo Characterization" Journal of Pharmacology and Experimental Therapeutics, 1994								

)

7